Learn About Our Key
Near-Term Milestones
Top line results expected forthcoming for our phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy‑related diarrhea.
We are supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected in 2024.
Learn About Our Key Near-Term Milestones
Top line results expected forthcoming for our phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy‑related diarrhea.
We are supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected in 2024.